NAV — Navco Pharmaceuticals Cashflow Statement
0.000.00%
- CA$0.57m
- CA$0.63m
Annual cashflow statement for Navco Pharmaceuticals, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2022 June 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Net Income/Starting Line | -0.094 | -2.15 | -1.72 |
Depreciation | |||
Amortisation | |||
Non-Cash Items | — | 0.947 | 0.851 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 0.083 | -0.62 | 0.544 |
Change in Accounts Receivable | |||
Change in Inventories | |||
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Change in Payable / Accrued Expenses | |||
Cash from Operating Activities | -0.01 | -1.78 | -0.253 |
Financing Cash Flow Items | — | -0.029 | 0 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 0 | 2.01 | 0.026 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -0.01 | 0.233 | -0.227 |